Description

Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C67H118N26O16—-[1]Mellor H, et al. The extended protein kinase C superfamily. Biochem J. 1998 Jun 1;332 ( Pt 2):281-92.|[2]Nishizuka Y (1995). Protein kinase C and lipid signaling for sustained cellular responses” (abstract). FASEB J. 9 (7): 484–96.–121545-65-1–1543.82–99.14–CC(C)[C@@H](C(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](C)NC(CNC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CC1=CC=CC=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–H2O : ≥ 50 mg/mL–PKC—-Epigenetics;TGF-beta/Smad–Peptides